Anhui Hongye Pharmaceutical Co., D.C. Lekadi tablets were approved for the birth of the 3rd domestic

Pharmaceutical Network January 20, January 18, NMPA official website shows that Anhui Hongye Pharmaceuticals according to the imitation of the 4 categories of reported production of hydrochloric acid Lekadi flat tablets were approved and treated as a review, becoming the third domestic.
is a commonly used antihypolytic drug, and in 2019 sales of lecades in China's public medical institutions and physical pharmacies terminals in Chinese cities were close to 300 million yuan, according to Mienet data.
Lecardipin hydrochloric acid is the third generation of calcium disinfectant-type channel blocker, with strong vascular selectivity, slow effect, strong bucking effect, long duration of action, small negative muscle effect and so on, suitable for the treatment of mild, moderate primary hypertension. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) and China's urban physical pharmacies terminal Lecadesping sales of nearly 300 million yuan.
market has maintained double-digit growth in recent years, with terminal sales growth of 77.88 percent in china's urban brick-and-mortar pharmacies by 2020.
China's urban physical drugstore terminal Le Cardil sales situation (unit: 10,000 yuan) Source: Minet China's urban physical pharmacy terminal competition pattern in the domestic market has 4 production enterprises, San Huayi, Xinlitai and Hongye Pharmaceuticals approved imitation, in addition to Italy's Recordati this product was approved for import.
although San Huaxuan's hydrochloric acid le Cardi flat tablets for the first imitation, but has not yet declared a consistent evaluation.
, Hongye Pharmaceuticals, the product is approved according to the imitation of 4 categories, as if through the consistent evaluation.
source: MiNet Database, NMPA